Calls
2
Paul Hudson
CEO, Sanofi
Win Rate
-
return
-
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 22
$57.22
-
Hudson argues innovation is the only thing that will be rewarded in pharma when all is said and done. Companies doing first-in-class/best-in-class drugs, researching rare diseases and unmet needs, will be what health systems pay for, and innovation should become more prominent as the political narrative changes.
Thematic ETFs
Long
Jan 22
$46.07
-
Hudson argues Sanofi is positioned for top-decile top-line growth after the obesity companies, with Q3 commercial performance outstanding and a late-stage pipeline approaching readouts over the next 12 to 24 months. He says innovation and improved business execution/resource allocation will protect Sanofi despite U.S.-Europe drug-pricing pressure.
Pharma & Biotech
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Paul Hudson has 2 trade ideas tracked on Buzzberg across 3 tickers since January 2026.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
